Logos Global Management »

Ocular Therapeutix shares owned by Logos Global Management

Quarter-by-quarter ownership of Ocular Therapeutix (OCUL) shares owned by Logos Global Management from 13F filings

Historical chart of Logos Global Management investment in Ocular Therapeutix

Tip: Access up to 7 years of quarterly data

All positions including Ocular Therapeutix held by Logos Global Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Ocular Therapeutix by Logos Global Management

Quarter filed Position value Share count Share price at filing
2023-12-31 $18M 4.0M 4.46

More positions owned by Logos Global Management

Cytokinetics Com New (CYTK)
Apellis Pharmaceuticals (APLS)
Sarepta Therapeutics Call Option (SRPT)
Ideaya Biosciences (IDYA)
Argenx Se Sponsored Adr (ARGX)
Olema Pharmaceuticals (OLMA)
Immunovant (IMVT)
Structure Therapeutics Sponsored Ads (GPCR)
Rocket Pharmaceuticals (RCKT)
Rayzebio
Ambrx Biopharma
Karuna Therapeutics Ord
Immunocore Hldgs Ads (IMCR)
Dyne Therapeutics (DYN)
Morphosys Sponsored Ads Call Option (MOR)

View all positions for Logos Global Management

Top funds holding Ocular Therapeutix

VR Adviser
Summer Road
Opaleye Management
Vanguard Group
Franklin Resources
Logos Global Management
Citadel Advisors
Deltec Asset Management
Millennium Management
Dr. Jeffrey R. Jay, M.D.
Banco Santander
Artia Global Partners
D. E. Shaw & Co
Essex Investment Management
Bank of New York Mellon

View all funds holding Ocular Therapeutix